Cytotoxicity News and Research

RSS

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.

14 May 2014

Angelica sinensis polysaccharides alleviate neuronal cell injury caused by oxidative stress

According to traditional Chinese medicine, the roles of Angelica sinensis correlate with tonifying the blood and promoting its circulation. Recent studies have shown that extracts of Angelica sinensis have antioxidative and neuroprotective effects.

10 Apr 2014

Study provides insight into the mechanisms underlying diabetic peripheral neuropathy

Iron overload can lead to cytotoxicity, and it is a risk factor for diabetic peripheral neuropathy. However, the underlying mechanism remains unclear.

13 Mar 2014

Blocking mechanisms for DNA repair may help to potentiate chemotherapy, says study

Chemotherapies are cancer treatments that work by inducing lesions in the DNA of tumour cells in order to inhibit their proliferation. However, the body naturally tries to repair these lesions, and thus reduces the efficacy of chemotherapy.

24 Feb 2014

arGEN-X reports that Phase Ib cancer study with ARGX-110 antibody meets translational development goals

arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met.

17 Dec 2013

Allied Healthcare Group commences first shipment of CardioCel into Europe

Allied Healthcare Group today announces it has commenced shipment of CardioCel into Europe after the Company received its first orders for the product from outside of Australia.

8 Nov 2013

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody product to enter the clinic this year.

17 Sep 2013

Study reveals role of cadherin receptor BT-R3 in killing action of Cry4B mosquito toxin

Researchers at The University of Texas at Dallas (UTD), led by Dr. Lee Bulla, have demonstrated for the first time the selective cytotoxicity of Bacillus thuringiensis subsp. israelensis Cry4B toxin is mediated by BT-R3.

27 Aug 2013

Combination of anti-nausea drug and turmeric spice target cancer cells

In a laboratory, preclinical study recently published by the journal Organic & Biomolecular Chemistry, Virginia Commonwealth University Massey Cancer Center researchers combined structural features from anti-nausea drug thalidomide with common kitchen spice turmeric to create hybrid molecules that effectively kill multiple myeloma cells.

20 Aug 2013

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Emergent BioSolutions Inc. today announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) molecule, ES414, at the 9th Annual Protein and Antibody Engineering Summit, currently underway in Boston, MA.

3 May 2013

Antioxidant boosts liver transplant outcomes

Infusion of N-acetylcysteine in liver donors can significantly improve the outcome of transplantation, research shows.

25 Feb 2013

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech, a member of the Roche Group, today announced positive results from Stage 1 of CLL11, a Phase III randomized study to investigate the efficacy and safety profile of the investigational medicine obinutuzumab (GA101) plus chlorambucil chemotherapy compared with chlorambucil alone in people with previously untreated chronic lymphocytic leukemia (CLL).

31 Jan 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013

Natural killer cell response detrimental to glioblastoma virotherapy

For the first time, researchers have demonstrated that the response of natural killer (NK) cells is detrimental to glioblastoma virotherapy, a novel way of treating malignant brain cancer by injecting a virus into the tumor.

5 Dec 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael

Approximately 20% of all breast cancer patients have overexpression of HER2 (human epidermal growth factor receptor 2), resulting in a more aggressive phenotype, and a poor prognosis.

28 Aug 2012

Biomimetic bioartificial livers and cell toxicity assays: an interview with Dr. Joris Braspenning, CEO Medicyte

Biomimetic bioartificial livers are liver organoids based on synthetic equivalents of the human extracellular matrix (ECM) which will be seeded with human cells.

1 Aug 2012

Safe optimal concentration of propolis against radiation-induced damage

Researchers determined the amount of propolis offering maximum protection against ionised radiations without being toxic to blood cells.

7 Jul 2012

Study represents starting point for future clinical applications using propolis

A team of researchers from the University of Valencia, the Universitat Politècnica de València, the University Hospital La Fe and the Universitat Autònoma de Barcelona conducted in vitro studies of cytotoxicity (cellular affection) to assess the optimal concentration level of propolis in which this natural substance extracted from bee resin would offer the maximum protection against ionised radiation and not be toxic for blood cells.

6 Jul 2012

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.

27 Jun 2012